NO980279L - Fremgangsmåte til detektering av lungesykdom - Google Patents

Fremgangsmåte til detektering av lungesykdom

Info

Publication number
NO980279L
NO980279L NO980279A NO980279A NO980279L NO 980279 L NO980279 L NO 980279L NO 980279 A NO980279 A NO 980279A NO 980279 A NO980279 A NO 980279A NO 980279 L NO980279 L NO 980279L
Authority
NO
Norway
Prior art keywords
lung
acceptable salt
sample
mucus
composition
Prior art date
Application number
NO980279A
Other languages
English (en)
Norwegian (no)
Other versions
NO980279D0 (no
Inventor
Jr Richard C Boucher
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of NO980279D0 publication Critical patent/NO980279D0/no
Publication of NO980279L publication Critical patent/NO980279L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO980279A 1995-07-31 1998-01-21 Fremgangsmåte til detektering av lungesykdom NO980279L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/509,052 US5628984A (en) 1995-07-31 1995-07-31 Method of detecting lung disease
PCT/US1996/012377 WO1997005195A1 (en) 1995-07-31 1996-07-24 Method of detecting lung disease

Publications (2)

Publication Number Publication Date
NO980279D0 NO980279D0 (no) 1998-01-21
NO980279L true NO980279L (no) 1998-01-21

Family

ID=24025091

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980279A NO980279L (no) 1995-07-31 1998-01-21 Fremgangsmåte til detektering av lungesykdom

Country Status (17)

Country Link
US (4) US5628984A (enExample)
EP (1) EP0841900B1 (enExample)
JP (2) JP3623237B2 (enExample)
KR (1) KR100283306B1 (enExample)
CN (1) CN1121441C (enExample)
AT (1) ATE276740T1 (enExample)
AU (1) AU705528B2 (enExample)
BR (1) BR9610059A (enExample)
CA (1) CA2226892A1 (enExample)
DE (1) DE69633449T2 (enExample)
ES (1) ES2229281T3 (enExample)
IL (1) IL122803A0 (enExample)
MX (1) MX9800933A (enExample)
NO (1) NO980279L (enExample)
NZ (1) NZ313864A (enExample)
WO (1) WO1997005195A1 (enExample)
ZA (1) ZA966425B (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
WO1996032138A1 (en) * 1995-04-13 1996-10-17 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6998121B2 (en) 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
WO1999005155A2 (en) 1997-07-25 1999-02-04 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
EP1011688B1 (en) * 1997-08-29 2005-02-02 The University of North Carolina at Chapel Hill Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
EP2258183A1 (en) * 1998-12-22 2010-12-08 The University of North Carolina at Chapel Hill Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
DE60015734D1 (de) 1999-02-26 2004-12-16 Inspire Pharmaceuticals Durham Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
JP2005508297A (ja) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｐ２ｙプリン受容体作用物質による関節潤滑
JP3823162B2 (ja) * 2001-07-31 2006-09-20 株式会社エイアンドティー 臨床検査分析装置、臨床検査分析方法および臨床検査分析プログラム
JP2005532254A (ja) * 2001-11-06 2005-10-27 インスパイアー ファーマシューティカルズ，インコーポレイティド 炎症性疾患を治療又は予防する方法
US20060196365A1 (en) * 2001-12-11 2006-09-07 Garman Michael H Combined water cooler and hot beverage maker
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
AU2004227358B8 (en) * 2003-03-31 2009-12-10 Targeted Genetics Corporation Compounds and methods to enhance rAAV transduction
JP5030587B2 (ja) 2003-06-26 2012-09-19 バイオトロン・リミテッド 抗ウイルスアシルグアニジン化合物および方法
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
EP1689705A4 (en) * 2003-11-24 2007-08-29 Univ North Carolina DIAGNOSTIC ANTIPROTOZOENOMENTS WITH CONDENSED RING AND PRODRUGS THEREOF
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070276020A1 (en) * 2004-03-08 2007-11-29 Boykin David W Dicationic Compounds For Activity Against Trichomonas Vaginalis
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
WO2006096757A2 (en) 2005-03-07 2006-09-14 The University Of North Carolina At Chapel Hill Inhibitors of reca activities for control of antibiotic-resistant bacterial pathogens
AU2006201739A1 (en) * 2005-05-05 2006-11-23 The University Of North Carolina At Chapel Hill Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
AU2006247077A1 (en) * 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US7964619B2 (en) 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
US8101636B2 (en) 2005-06-03 2012-01-24 The University Of North Carolina At Chapel Hill Linear dicationic terphenyls and their aza analogues as antiparasitic agents
US20100249175A1 (en) * 2005-12-02 2010-09-30 Wilson W David Dicationic compounds which selectively recognize G-quadruplex DNA
WO2007127464A2 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
AU2008266856A1 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of PFKFB3 inhibitors with anti-neoplastic activities
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
US8551534B2 (en) 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
WO2009051796A2 (en) * 2007-10-17 2009-04-23 The University Of North Carolina At Chapel Hill 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents
KR20100135886A (ko) 2008-04-09 2010-12-27 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 액틴 세포 골격의 재배열 및 세포간 갭 형성을 조절하는 방법
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
CA2768154C (en) 2009-07-13 2018-02-13 Irix Pharmaceuticals Synthesis of prostanoids
CA2768582C (en) 2009-07-24 2017-02-14 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
RU2012108849A (ru) * 2009-08-10 2013-09-20 П2-Сайенс Апс Utp для диагностирования стеноза и других состояний ограниченного кровотока
JP5922111B2 (ja) * 2010-06-23 2016-05-24 ピーツー−サイエンス・エペイエス 充血剤注入と同時に血圧測定を行う診断目的の動脈用複合カテーテル
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
SG10201708931XA (en) 2012-12-17 2017-12-28 Parion Sciences Inc Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
CN105592851A (zh) 2013-09-30 2016-05-18 帕西昂Api服务公司 利用复分解反应的前列腺素和前列腺素中间体的新合成途径
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN104306028B (zh) * 2014-09-26 2016-08-17 张清玲 一种用于呼吸道细菌16S rRNA基因序列检测的痰液收集方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
US10413583B2 (en) 2016-11-30 2019-09-17 The University Of Chicago Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
GB2604314A (en) 2017-09-22 2022-09-07 Nerudia Ltd Device, system and method
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
WO2020131974A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
BR112021018456A2 (pt) 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055465A (en) * 1962-09-27 1967-01-18 Vantorex Ltd Allergenic aerosol compositions
BE639386A (enExample) * 1962-10-30
US4132600A (en) * 1977-06-01 1979-01-02 Massachusetts Institute Of Technology Enzymatic noninvasive method for detecting cancer
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
FR2571257A1 (fr) * 1984-08-06 1986-04-11 Gros Pierre Composition destinee a l'humidification de la muqueuse rhino-pharyngee
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US4950477A (en) * 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
US6133247A (en) 2000-10-17
US6214536B1 (en) 2001-04-10
CN1191553A (zh) 1998-08-26
JPH11509759A (ja) 1999-08-31
EP0841900B1 (en) 2004-09-22
ATE276740T1 (de) 2004-10-15
EP0841900A4 (enExample) 1998-06-10
EP0841900A1 (en) 1998-05-20
JP2003073280A (ja) 2003-03-12
WO1997005195A1 (en) 1997-02-13
MX9800933A (es) 1998-05-31
ES2229281T3 (es) 2005-04-16
NO980279D0 (no) 1998-01-21
US5628984A (en) 1997-05-13
DE69633449T2 (de) 2006-04-27
ZA966425B (en) 1997-02-19
BR9610059A (pt) 1999-03-02
NZ313864A (en) 2000-04-28
IL122803A0 (en) 1998-09-16
US5902567A (en) 1999-05-11
JP3623237B2 (ja) 2005-02-23
AU6639996A (en) 1997-02-26
KR19990036011A (ko) 1999-05-25
DE69633449D1 (de) 2004-10-28
AU705528B2 (en) 1999-05-27
KR100283306B1 (ko) 2001-03-02
CA2226892A1 (en) 1997-02-13
CN1121441C (zh) 2003-09-17

Similar Documents

Publication Publication Date Title
NO980279L (no) Fremgangsmåte til detektering av lungesykdom
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
MXPA01008547A (es) Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
JPH09501413A (ja) 滞留肺分泌物の治療方法
ATE268605T1 (de) Pharmazeutische akzeptabel dnase zusammensetzung
MY120023A (en) Method of treating dry eye disease with uridine triphosphates and related compounds.
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
BR9915592A (pt) Processos para conversão das regiões cristalinas meta-estáveis e/ou amorfas de partìculas pré-formadas para um estado essencialmente cristalino para tratamento de uma condição alérgica e/ou inflamatória do nariz ou dos pulmões, para tratamento de doença pulmonar obstrutiva crÈnica (copd), rinite ou asma e para tratamento de doenças de intestino inflamatório (ibd), doença de crohn ou colite ulcerativa, formulação farmacêutica, uso da mesma, partìculas no estado essencialmente cristalino, e, partìculas de lactose mono-hidratada no estado essencialmente cristalino
WO1997035591A3 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
KR100518066B1 (ko) 우리딘 트리포스페이트 및 관련 화합물로 기관지염을 치료하는방법
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
ES2122015T3 (es) Uso de urodilatina en enfermedades pulmonares y bronquiales.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
EP1080225A4 (en) COMPOSITIONS AND METHODS FOR THE PULMONAL ADMINISTRATION OF NUCLEIC ACIDS
KR890012942A (ko) 5-치환된 오르니틴 유도체
HUP0201629A2 (hu) Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
Saito et al. Excretion in bile and clinical study of T-1220 (piperacillin) in biliary tract diseases (author's transl)
RU95120783A (ru) Способ профилактики и лечения атеросклероза
Delaunois et al. Characteristics, diagnosis and treatment of non-tuberculous mycobacteria in non-immunocomprised patients.
Bishara et al. Lichenoid reaction in bone marrow transplants suffering from chronic GVHD is associated with HLA-DQW1
SE9802555D0 (sv) New pharmaceutical preparation and method
NO930711L (no) Aminosyrederivater ringsluttet i den c-terminale ende

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application